Strong domestic sales are expected to lift Q3FY26 pharma revenues by 8-11%, while US generic Revlimid impacts weigh on ...
Redemption requests rise across major private credit managers after high-profile corporate failures unsettle investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback